Lung cancer in HIV infected patients: facts, questions and challenges

J Cadranel, D Garfield, A Lavolé, M Wislez, B Milleron, C Mayaud

AIDS related mortality has fallen sharply in industrialised countries since 1996 following the introduction of highly active antiretroviral therapy. This has been accompanied by an increase in the proportion of deaths attributable to non-AIDS defining solid tumours, especially lung cancer. The risk of developing lung cancer seems to be higher in HIV infected subjects than in the general population of the same age, partly because the former tend more frequently to be smokers and, especially, intravenous drug users. The carcinogenic role of the antiretroviral nucleoside drugs and their interaction with smoking needs to be examined. Interestingly, there is no clear relationship between the degree of immunosuppression and the risk of lung cancer, so the reason for the increased risk is unknown. The mean age of HIV infected patients at the time of lung cancer diagnosis is 45 years and most are symptomatic. Lung cancer is diagnosed when locally advanced or metastatic (stage III–IV) in 75–90% of cases, similar to patients with unknown HIV status. Adenocarcinoma is the most frequent histological type. The prognosis is worse in HIV infected patients than in the general lung cancer population. Efficacy and toxicity data for chemotherapy and radiation therapy are few and imprecise. Surgery remains the treatment of choice for localised disease in patients with adequate pulmonary function and general good health, regardless of immune status. Prospective clinical trials are needed to define the optimal detection and treatment strategies for lung cancer in HIV infected patients.

lung cancers were reported in HIV infected (HIV+) patients early in the AIDS epidemic. A relatively high frequency of adenocarcinoma and advanced disease at diagnosis was noted, as was the poor prognosis. Surprisingly, however, no correlation was noted between lung cancer and the degree of immune deficiency at diagnosis.

Subsequently, some epidemiological and clinical series suggested an increased risk of lung cancer in HIV+ patients, and again confirmed its worse prognosis. However, not all such studies noted such an increase. Then, in 1996, mortality due to AIDS began to decrease sharply in industrialised countries following the introduction of highly active antiretroviral treatment (HAART). However, this was accompanied by an increase in the proportion of deaths due to non-AIDS defining malignancies including lung cancer. Moreover, in two recent epidemiological studies, lung cancer was the leading fatal non-AIDS defining malignancy, tending to confirm the suspicion of an increased risk of lung cancer in the HIV+ population. In fact, lung cancer now accounts for three times more cancer deaths than non-Hodgkin’s lymphoma, 11–40% of deaths from non-AIDS defining cancers, and 1.6–4.25% of all deaths in HIV+ patients.

This review examines current epidemiological data and factors which might explain this putative increased risk of lung cancer in the HIV+ population, as well as the clinical, radiological, pathological, prognostic, and therapeutic features in this setting, particularly in the HAART era.

SEARCH STRATEGY

The search strategy was conducted using PubMed, without limitation of date, to identify potentially relevant articles using the following keyword terms: (1) for clinical, radiological, pathological, and therapeutic aspects: [lung cancer or lung carcinoma] and [HIV or AIDS]; (2) for epidemiological and mortality aspects: [AIDS or HIV] and [lung cancer or lung carcinoma or non-AIDS defining malignancy] and [epidemiology or mortality]; (3) we also looked for [genotoxicity or carcinogenotoxicity] and [anti-retroviral drugs]. However, our research was limited to articles published in English, with an abstract available, and concerning studies in humans. Papers dealing with Hodgkin’s and non-Hodgkin’s lymphoma and Kaposi’s sarcoma were excluded from the analysis, except for data on interactions between HAART and chemotherapy and the impact of chemotherapy on HIV plasma viral load and CD4 cell counts. Original papers were mainly cited, with minimal use of case reports and general reviews.

EPIDEMIOLOGY

Risk for lung cancer in the HIV+ population

The possibility of an increased risk was initially raised by epidemiological studies using the standardised incidence ratio (SIR), the ratio of the observed incidence of lung cancer in the HIV+ study population to the expected incidence in the same general lung cancer population. The expected incidence is calculated from the population. In fact, lung cancer now accounts for three times more cancer deaths than non-Hodgkin’s lymphoma, 11–40% of deaths from non-AIDS defining cancers, and 1.6–4.25% of all deaths in HIV+ patients.

This review examines current epidemiological data and factors which might explain this putative increased risk of lung cancer in the HIV+ population, as well as the clinical, radiological, pathological, prognostic, and therapeutic features in this setting, particularly in the HAART era.

SEARCH STRATEGY

The search strategy was conducted using PubMed, without limitation of date, to identify potentially relevant articles using the following keyword terms: (1) for clinical, radiological, pathological, and therapeutic aspects: [lung cancer or lung carcinoma] and [HIV or AIDS]; (2) for epidemiological and mortality aspects: [AIDS or HIV] and [lung cancer or lung carcinoma or non-AIDS defining malignancy] and [epidemiology or mortality]; (3) we also looked for [genotoxicity or carcinogenotoxicity] and [anti-retroviral drugs]. However, our research was limited to articles published in English, with an abstract available, and concerning studies in humans. Papers dealing with Hodgkin’s and non-Hodgkin’s lymphoma and Kaposi’s sarcoma were excluded from the analysis, except for data on interactions between HAART and chemotherapy and the impact of chemotherapy on HIV plasma viral load and CD4 cell counts. Original papers were mainly cited, with minimal use of case reports and general reviews.

EPIDEMIOLOGY

Risk for lung cancer in the HIV+ population

The possibility of an increased risk was initially raised by epidemiological studies using the standardised incidence ratio (SIR), the ratio of the observed incidence of lung cancer in the HIV+ study population to the expected incidence in the same general lung cancer population. The expected incidence is calculated from the population. In fact, lung cancer now accounts for three times more cancer deaths than non-Hodgkin’s lymphoma, 11–40% of deaths from non-AIDS defining cancers, and 1.6–4.25% of all deaths in HIV+ patients.

This review examines current epidemiological data and factors which might explain this putative increased risk of lung cancer in the HIV+ population, as well as the clinical, radiological, pathological, prognostic, and therapeutic features in this setting, particularly in the HAART era.

SEARCH STRATEGY

The search strategy was conducted using PubMed, without limitation of date, to identify potentially relevant articles using the following keyword terms: (1) for clinical, radiological, pathological, and therapeutic aspects: [lung cancer or lung carcinoma] and [HIV or AIDS]; (2) for epidemiological and mortality aspects: [AIDS or HIV] and [lung cancer or lung carcinoma or non-AIDS defining malignancy] and [epidemiology or mortality]; (3) we also looked for [genotoxicity or carcinogenotoxicity] and [anti-retroviral drugs]. However, our research was limited to articles published in English, with an abstract available, and concerning studies in humans. Papers dealing with Hodgkin’s and non-Hodgkin’s lymphoma and Kaposi’s sarcoma were excluded from the analysis, except for data on interactions between HAART and chemotherapy and the impact of chemotherapy on HIV plasma viral load and CD4 cell counts. Original papers were mainly cited, with minimal use of case reports and general reviews.

EPIDEMIOLOGY

Risk for lung cancer in the HIV+ population

The possibility of an increased risk was initially raised by epidemiological studies using the standardised incidence ratio (SIR), the ratio of the observed incidence of lung cancer in the HIV+ study population to the expected incidence in the same general lung cancer population. The expected incidence is calculated from the population. In fact, lung cancer now accounts for three times more cancer deaths than non-Hodgkin’s lymphoma, 11–40% of deaths from non-AIDS defining cancers, and 1.6–4.25% of all deaths in HIV+ patients.

This review examines current epidemiological data and factors which might explain this putative increased risk of lung cancer in the HIV+ population, as well as the clinical, radiological, pathological, prognostic, and therapeutic features in this setting, particularly in the HAART era.

SEARCH STRATEGY

The search strategy was conducted using PubMed, without limitation of date, to identify potentially relevant articles using the following keyword terms: (1) for clinical, radiological, pathological, and therapeutic aspects: [lung cancer or lung carcinoma] and [HIV or AIDS]; (2) for epidemiological and mortality aspects: [AIDS or HIV] and [lung cancer or lung carcinoma or non-AIDS defining malignancy] and [epidemiology or mortality]; (3) we also looked for [genotoxicity or carcinogenotoxicity] and [anti-retroviral drugs]. However, our research was limited to articles published in English, with an abstract available, and concerning studies in humans. Papers dealing with Hodgkin’s and non-Hodgkin’s lymphoma and Kaposi’s sarcoma were excluded from the analysis, except for data on interactions between HAART and chemotherapy and the impact of chemotherapy on HIV plasma viral load and CD4 cell counts. Original papers were mainly cited, with minimal use of case reports and general reviews.

EPIDEMIOLOGY

Risk for lung cancer in the HIV+ population

The possibility of an increased risk was initially raised by epidemiological studies using the standardised incidence ratio (SIR), the ratio of the observed incidence of lung cancer in the HIV+ study population to the expected incidence in the same general lung cancer population. The expected incidence is calculated from the population. In fact, lung cancer now accounts for three times more cancer deaths than non-Hodgkin’s lymphoma, 11–40% of deaths from non-AIDS defining cancers, and 1.6–4.25% of all deaths in HIV+ patients.

This review examines current epidemiological data and factors which might explain this putative increased risk of lung cancer in the HIV+ population, as well as the clinical, radiological, pathological, prognostic, and therapeutic features in this setting, particularly in the HAART era.

SEARCH STRATEGY

The search strategy was conducted using PubMed, without limitation of date, to identify potentially relevant articles using the following keyword terms: (1) for clinical, radiological, pathological, and therapeutic aspects: [lung cancer or lung carcinoma] and [HIV or AIDS]; (2) for epidemiological and mortality aspects: [AIDS or HIV] and [lung cancer or lung carcinoma or non-AIDS defining malignancy] and [epidemiology or mortality]; (3) we also looked for [genotoxicity or carcinogenotoxicity] and [anti-retroviral drugs]. However, our research was limited to articles published in English, with an abstract available, and concerning studies in humans. Papers dealing with Hodgkin’s and non-Hodgkin’s lymphoma and Kaposi’s sarcoma were excluded from the analysis, except for data on interactions between HAART and chemotherapy and the impact of chemotherapy on HIV plasma viral load and CD4 cell counts. Original papers were mainly cited, with minimal use of case reports and general reviews.
observed incidence of lung cancer in the general population (assumed to be HIV−), assuming that the HIV+ population is exposed to the same known risk factors for lung cancer as the general population of similar age and same sex. The incidence of lung cancer in the general population is obtained from regional or national cancer registries.

The SIR for lung cancer in the HIV+ population was determined in studies carried out either before the HAART era (pre-1996) or both before and during the HAART era (1996–9) showing that the risk of lung cancer in the HIV+ population (SIR >1) but, surprisingly, two studies covering both periods showed an even higher risk of lung cancer in the HIV+ population during the HAART period.

Pre-HAART studies

Data on cancers in 302 834 AIDS patients diagnosed from 1978 to 1996 in 11 regions of the USA showed that lung cancer was the most frequent non-AIDS defining malignancy with a SIR of 4.5. The risk was higher among women (SIR = 7.1) than men (SIR = 4.3). Similarly, in two other studies the SIR for lung cancer was 6.5 among 26 181 American patients with AIDS (35/36 (97%) were men), and 3.8 in 3616 Australian patients with AIDS diagnosed during 1980–93. Finally, in one study performed in Italy the SIR for lung cancer was 2.11 in 20 000 HIV+ subjects smoke 20/day in HIV+ patients, although the duration of exposure was shorter in the former group.

Pre-HAART vs HAART studies

A prospective study of 77 025 HIV+ patients treated in France in the pre-HAART period (1992–5) compared with the HAART period (1996–9) showed that the risk of lung cancer in the HIV+ population during the pre-HAART period was not different from that in the general population, except in the subgroup of male IVDUs (SIR = 3.16), although the number of such patients was small (n = 6). In contrast, during the HAART period, the risk of lung cancer was higher in the HIV+ population than in the general population. The risk differed according to the HIV transmission route and sex (SIR = 1.78 for homosexuals, 1.92 for heterosexuals, 4.70 for IVDUs, 2.12 for men, and 6.59 for women).

Similarly, a study in England found that the incidence of lung cancer was 0.8/100 000 HIV+ patients (n = 2) in the pre-HAART period, the same as the general population in 1996 (0.75/100 000), but 6.7/100 000 HIV+ patients (n = 9) in the HAART period resulting in a relative risk of 8.93. The risk of lung cancer was also higher in 7304 HIV+ patients in a Swiss HIV cohort study than in the general population (SIR = 3.2). However, there was no clear impact of HAART on the SIR for lung cancer in HIV+ patients.

Factors which may explain the recent increased risk of lung cancer in the HIV+ population

Smoking

The increased risk of lung cancer might reflect different smoking habits, as surveys suggest that HIV+ subjects smoke more than the general population. One study found more smokers among 274 HIV+ patients than in 1038 HIV− subjects of similar age (57% v 33%, p<0.001). In four epidemiological studies the risk of lung cancer in the HIV+ population was highest among IVDUs, a group also known to be heavy smokers (table 1). In one study, HIV+ lung cancer patients smoked 40 cigarettes/day compared with 20/day in HIV− patients, although the duration of exposure was shorter in the former group. Finally, in South Africa where the incidence of HIV+/AIDS is high but smoking low, there was no increased risk of lung cancer and, in one study, no cases of lung cancer were found in HIV+ patients who did not smoke.

However, lung cancer cases still remained 2.5 times higher than expected, even assuming that all cohort patients were smokers. This led to the opinion that smoking was not the only factor responsible for the rise seen. Furthermore, the most common type of lung cancer in HIV+ patients is adenocarcinoma, the subtype least strongly associated with smoking (see below). The increased risk of lung cancer in the HIV+ population might therefore be explained by heavier smoking, even if other factors may also be causative.
Increased susceptibility to carcinogens

Evidence is lacking that HIV+ patients are more susceptible to carcinogens contained in tobacco smoke. Indeed, studies have shown that HIV+ patients with lung cancer smoke less, as much as, or more than lung cancer patients with undetermined HIV status (table 2).10 42 45

The possible role of genomic instability in the increased lung cancer risk among HIV+ patients is suggested by a study of 16 polymorphic markers on eight chromosome arms frequently deleted in lung cancer.44 Tumour samples from 11 HIV+ patients with lung cancer and 35 patients who were assumed to be HIV− showed that the two groups did not differ with regard to the frequency of loss of heterozygosity (LOH) or type of LOH, except at two loci. In the HIV+ patients LOH was more frequent on chromosome arm 5q22 (86% v 39%; p = 0.007) and less frequent at 3p14.2 (FHIT gene) (23% v 77%; p = 0.03). The significance of these differences, if any, is unknown.

However, microsatellite alteration was six times more frequent in the HIV+ patients (0.18 v 0.03; p<0.001) and was widespread.43 Moreover, no microsatellite alteration was found in normal tissues, arguing against factors affecting DNA repair such as HIV, antiretroviral drugs, chronic immune deficiency, chemotherapy, or radiotherapy. It could not be determined whether microsatellite alteration was an early or late event, but the authors felt it could have an important role in lung cancer development.44

Two nucleoside analogue reverse transcriptase inhibitors, zidovudine (AZT) and lamivudine—part of the HAART regime—are DNA replication chain terminators and can be genotoxic. In animal models, AZT in particular is a moderately strong transplacental carcinogen for up to 2 years after birth and can be incorporated into the DNA of many fetal organs. This damage is dose related and can be significant. In some organs telomeres are shortened. In human infant cord blood the combination of AZT and lamivudine produces DNA damage.46 Thus, although not yet shown to be carcinogenic in humans, these two drugs could conceivably act as co-carcinogens, along with tobacco smoke, in causing lung cancer.

Risk of lung cancer in the HAART era

There are conflicting data as to whether patients developing lung cancer since the introduction of HAART are older, which could account for some of the increase in the incidence of lung cancer. In HIV+/AIDS patients ≥60 years of age, twice as many patients with lung cancer were observed (n = 105) as were expected (n = 54.3), with a relative risk of 1.9.47 In another study men with non-AIDS defining cancers were 3 years older in the HAART era.21

Two other factors might also explain the difference in lung cancer risk between the pre-HAART and HAART periods. Firstly, the increase in life expectancy conferred by HAART (currently more than 5 years)47 might explain the onset of smoking related diseases such as lung cancer, the risk of which increases with pack-years smoked. The rate of lung cancer increased from 1% to 6% among HIV+ patients admitted to a French chest unit in 1993–9 (p = 0.004), while...
the number of HIV+ patients admitted to hospital for all causes fell by $-50\%$ during that period.\textsuperscript{46} Secondly, the decline in deaths from AIDS might lead to the development of causes linked to other competing risks such as smoking.\textsuperscript{17} For example, mortality due to non-AIDS malignancies rose from $6.4\%$ in 1994 to 10.9\% in 1998 in San Francisco,\textsuperscript{47} with lung cancer being the leading cause of non-AIDS cancer deaths. However, the absolute number of lung cancer deaths remained about the same during the 4 year period.\textsuperscript{14 19}

The even greater increase in risk among HIV+ women during the HAART period is of interest,\textsuperscript{17 19} although one group felt that the SIR of lung cancer among HIV+ women may have been overestimated.\textsuperscript{22} Over-representation of IVDUs (a group usually comprised of heavy smokers) among HIV+ women with lung cancer may be one explanation. In one study 50\% of HIV+ women were IVDUs\textsuperscript{22} and in another the percentage of IVDUs in HIV+ women with non-AIDS defining cancers rose from 20\% to 30\% between the pre-HAART and HAART periods.\textsuperscript{21} Furthermore, in an American women cohort study including 2059 HIV+ patients and 569 HIV uninfected at-risk women enrolled between 1994 and 1996, the SIR for lung cancer was 6.3 (95\% CI 2.7 to 11.3, $p<0.0001$) compared with the surveillance, epidemiology, and end results (SEER) rates and was not different between the pre-HAART and HAART periods.\textsuperscript{21} Interestingly, the SIR for lung cancer was similarly increased (6.9, 95\% CI 0.8 to 19.3, $p=0.07$) in HIV− at-risk women compared with the general population, which suggests that the high rates of lung cancer are not associated with HIV infection. Instead, they are probably attributable to high rates of cigarette smoking found in both HIV+ (57.1\%) and HIV− at-risk women (65.7\%).\textsuperscript{46} On the other hand, the far higher SIR for lung cancer in HIV+ women relative to men in the HAART period could reflect the higher susceptibility of women to lung cancer with the same degree of tobacco exposure.\textsuperscript{20 52}

Current epidemiological data therefore seem to show an increase in the risk of lung cancer in the HIV+ population, a group more likely than the general population to smoke.\textsuperscript{39} This risk appears to be particularly high among IVDUs and women. Any data on the risk of lung cancer in women IVDUs who are smokers (both HIV+ and HIV−) would be of interest. The role of risk factors other than smoking (such as particular susceptibility to tobacco carcinogens, severity and duration of immunosuppression, viral co-infection, possible mutagenicity of antiretroviral drugs\textsuperscript{55 54}) remains to be investigated.

**DEMOGRAPHIC, CLINICAL, AND RADIOLOGICAL CHARACTERISTICS**

The first cases of lung cancer in HIV+ patients were reported in 1984.\textsuperscript{1} Since then, case reports,\textsuperscript{55 57} descriptive reviews,\textsuperscript{10 56 60} and case-control series have been published.\textsuperscript{4 5 42 45 61 62} It is noteworthy that the control groups in case-control series consisted of subjects with unknown HIV status rather than exclusively HIV− subjects. This bias may minimise observed differences between the HIV+ and control populations, particularly if the control group is age matched with the HIV+ population.

Lung cancer has been reported to occur at a significantly younger age among HIV+ patients than in the general lung cancer population.\textsuperscript{4 5 42 45 63} especially in a comparative study in which the subjects were not matched for age (mean 45 years (range 38–49) v 62 years (range 36–75)).\textsuperscript{41}

Men are significantly more at risk than women, with a male:female sex ratio of $9.1 \pm 1$.\textsuperscript{4 5 42 45 61 62} This reflects the epidemiology of lung cancer and HIV/AIDS, both of which have affected men more than women for reasons linked to the respective risk factors. Male predominance may become less marked in the future, as suggested by a recent epidemiological study in which SIR for lung cancer was higher in HIV+ women than in men.\textsuperscript{17} This trend may arise from the increase in female smokers in the general population and a narrowing of the male:female ratio in the HIV+ population.\textsuperscript{41} The proportion of smokers is high (>85\%) among HIV+ patients with lung cancer, and in HIV+ IVDUs (96\%),\textsuperscript{27} but similar to controls of similar age.\textsuperscript{42 45} Duration of smoking and extent of tobacco used are also similar, with both parameters tending to be higher in studies involving large proportions of HIV+ IVDUs (table 2).\textsuperscript{41 64}

The distribution of the different modes of HIV transmission in patients with lung cancer is similar to that of the general HIV+ population. The degree of immune deficiency is generally moderate at the time of lung cancer diagnosis with a mean CD4+ cell count of 250/mm$^3$ (range 121–364/mm$^3$). The proportion of patients with CD4+ cell counts $<200$mm$^3$ varies widely from 9\% to 54\%,\textsuperscript{4 5 32 33 45} At the time of diagnosis of lung cancer in HIV+ patients, 25–50\% already have known AIDS. However, this proportion has tended to be lower in more recent series.\textsuperscript{62}

Most patients are symptomatic at diagnosis, reflecting extensive disease. Indeed, lung cancer is diagnosed when locally advanced or metastatic (stage IIIB–IV) in 75–90\% of HIV+ patients, similar to that in age matched lung cancer control groups.\textsuperscript{3 5 42 45 61} Symptoms are variable, non-specific, and usually multiple.\textsuperscript{59 61} Respiratory symptoms include cough (40–86\%), chest pain (25–57\%), dyspnoea (10–57\%), and haemoptysis (10–29\%). Their frequency and distribution do not differ from those in age matched lung cancer controls,\textsuperscript{30 61} and the same is true of non-respiratory symptoms. Performance status (PS) $\geqslant 2$ was 37–57\% before 1996 but $\sim 30\%$ subsequently.\textsuperscript{44} The general health status of HIV+ patients with lung cancer appears to be less than that of HIV indeterminate controls (29\% v 7\%, $p=0.01$ in one series\textsuperscript{61}).

A few small studies have examined the radiological features in HIV+ patients with lung cancer.\textsuperscript{40 44 45 51} Most primaries were T2\textsuperscript{40} but, in HIV+ patients with one or more nodules on the CT scan, only 4\% had lung cancer.\textsuperscript{40} The most common finding is a mass (80–100\%) measuring $\sim 4.5$ cm

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Histological distribution of lung cancer in HIV+ patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sridhar\textsuperscript{a} (n = 19)</td>
</tr>
<tr>
<td>Histology, n (%)</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>5 (31)</td>
</tr>
<tr>
<td>Squamous cell</td>
<td>6 (37)</td>
</tr>
<tr>
<td>Large cell</td>
<td>2 (13)</td>
</tr>
<tr>
<td>Other</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Small cell</td>
<td>1 (6)</td>
</tr>
<tr>
<td>Stage (%)</td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>21</td>
</tr>
<tr>
<td>III–IV</td>
<td>79</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Histology data were not provided for all studies.
studies found that extensive pleural disease in the absence of to age matched lung cancer control groups. Thus, the otherwise the distribution of the histological types is similar cancer than in HIV

These differences were not statistically significant. Other (table 3). Adenocarcinoma was the histological type most frequently observed in all but two studies, but otherwise the distribution of the histological types is similar to age matched lung cancer control groups. Thus, the predominance of adenocarcinoma in HIV+ patients reflects general changes in the distribution of the histological types of lung cancer. Adenocarcinoma superseded squamous cell carcinoma in the general population of the USA in the 1990s and, subsequently, in other industrialised countries.

Pathological findings
Non-small cell lung cancer (NSCLC) represents 86–94% of HIV+ patients with lung cancer while small cell carcinoma has been reported in only 5–13%. Of all HIV+ cases with NSCLC, adenocarcinoma represents 31–50%, squamous cell carcinoma 19–52%, and large cell carcinoma 9–19% of NSCLC, adenocarcinoma represents 31–50%, squamous cell carcinoma in the general population of the USA in the 1990s and, subsequently, in other industrialised countries.

Prognostic factors
The prognosis of lung cancer was poorer in HIV+ patients than in subjects with undetermined HIV serostatus in all case-control studies published to date (table 4). However, in this latter study the median survival of the control group was particularly low (4 months) compared with that in other studies also matched for age (7–11 months). Regardless of TNM stage, median survival time among HIV+ patients with lung cancer is 4.5 months (range 3–9) compared with 10 months (range 4–12.5) in age matched HIV− controls (table 4). The 1 year survival rate is about 10% (range 0–15%) among HIV+ patients and about 40% (range 20–50%) in controls. In most published studies no HIV+ patients were living 2 years after diagnosis compared with 0–25% of controls (table 4). However, a recent study found a 2 year survival rate of 10% both in the periods 1990–1995 and 1996–2000. Unfortunately, 24 month survival was the same in both the pre-HAART and HAART periods for those with AIDS and lung cancer (10%). Finally, in older series death tended to be linked to HIV infection (65%) while in more recent series it is mainly due to lung cancer itself (75–88%).

Very few data are available on prognostic factors in HIV+ patients with lung cancer. In a single health system, in an historical cohort study of 1155 lung cancer patients, the effect of 56 co-morbidities including HIV/AIDS on survival was evaluated in univariate and multivariate models adjusted for recognised prognostic factors (age, sex, smoking status,

### Table 4 Comparison of survival rates in HIV+ and HIV indeterminate patients with lung cancer

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (months)</td>
<td>1/5</td>
<td>3/10</td>
<td>8/12.5</td>
<td>5/10</td>
<td>4/7</td>
<td>9/11</td>
<td>4/4</td>
</tr>
<tr>
<td>% alive at 1 year</td>
<td>0/0</td>
<td>0/32</td>
<td>10/50</td>
<td>10/48</td>
<td>0/20</td>
<td>15/41</td>
<td>11/22</td>
</tr>
<tr>
<td>p value</td>
<td>&lt;0.01</td>
<td>0.002</td>
<td>0.0035</td>
<td>0.0001</td>
<td>&lt;0.003</td>
<td>0.01</td>
<td>0.55</td>
</tr>
</tbody>
</table>

*Stage IV only compared.
†Males only analysed.
‡Stages IIIb/IV only.

(range 2.0–8.0), more often peripheral (11/15) than central (4/15), and located in the upper lobes (10/15). When the lung cancer was peripheral, more patients (15/18) had a history of tuberculosis or Pneumocystis jiroveci pneumonia than did those with a central lesion (3/11, p = 0.005) in one pre-HAART study.

One study showed a higher frequency of mediastinal adenopathy (6/7 v 4/14) in HIV+ patients with adenocarcinoma type lung cancer than in HIV− patients with adenocarcinoma, but these differences were not statistically significant. Other studies found that extensive pleural disease in the absence of a primary was not uncommon.

### Table 5 Surgical outcomes of HIV+ patients with lung cancer

<table>
<thead>
<tr>
<th>Author</th>
<th>Patient</th>
<th>CD4+</th>
<th>Stage</th>
<th>Treatment</th>
<th>Survival (months)</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spano et al.</td>
<td>1</td>
<td>390</td>
<td>IIIA</td>
<td>S</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>570</td>
<td>IA</td>
<td>S</td>
<td>36</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>420</td>
<td>IB</td>
<td>S</td>
<td>77 (alive)</td>
<td>0</td>
</tr>
<tr>
<td>Massera et al.</td>
<td>4</td>
<td>343</td>
<td>II</td>
<td>CT-S-RT</td>
<td>17 (alive)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>200</td>
<td>II</td>
<td>CT-S</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>410</td>
<td>IB</td>
<td>S</td>
<td>3 (alive)</td>
<td>0</td>
</tr>
<tr>
<td>Sridhar et al.</td>
<td>7</td>
<td>&lt;200</td>
<td>IIIA</td>
<td>S</td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>&lt;200</td>
<td>IIIB</td>
<td>S</td>
<td>20 (alive)</td>
<td>0</td>
</tr>
<tr>
<td>Vyzula et al.</td>
<td>9</td>
<td>19</td>
<td>IA</td>
<td>S</td>
<td>5</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>524</td>
<td>IA</td>
<td>S</td>
<td>3</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>99</td>
<td>IA</td>
<td>S</td>
<td>12 (alive)</td>
<td>–</td>
</tr>
<tr>
<td>Lavole et al.</td>
<td>12</td>
<td>–</td>
<td>I</td>
<td>S</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>371</td>
<td>I</td>
<td>S</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>653</td>
<td>I</td>
<td>S</td>
<td>39</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>369</td>
<td>IIIB</td>
<td>S</td>
<td>1.5</td>
<td>Infection, death</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>350</td>
<td>IIIA</td>
<td>S</td>
<td>31</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>550</td>
<td>II</td>
<td>S</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>439</td>
<td>IIIA</td>
<td>CT-S</td>
<td>22</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td>407</td>
<td>IA</td>
<td>CT-S</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>280</td>
<td>IIIA</td>
<td>CT-S</td>
<td>28</td>
<td>0</td>
</tr>
<tr>
<td>Thurer et al.</td>
<td>21</td>
<td>&lt;200</td>
<td>IA</td>
<td>Lobectomy</td>
<td>5</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>&lt;200</td>
<td>IA</td>
<td>Lobectomy</td>
<td>5</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td>&lt;200</td>
<td>IA</td>
<td>Lobectomy</td>
<td>3.5</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>963</td>
<td>IA</td>
<td>Wedge</td>
<td>12 (alive)</td>
<td>0</td>
</tr>
</tbody>
</table>

S, surgery; CT-S, chemotherapy following surgery; CT-S-RT, chemotherapy, surgery and radiotherapy.

*Five patients had lobectomy, one had a pneumonectomy.
The prevalence of AIDS/HIV patients in the cohort study was 0.7%; the median survival of HIV+ patients with lung cancer was 4.8 months compared with 10.3 months for the entire study population (hazard ratio (HR) = 2.33, p = 0.002). HIV/AIDS was a predictor of survival adjusted for baseline co-morbidities (HR = 4.77, p = 0.0001), other co-morbidities (HR = 3.69, p = 0.0008), and treatments (HR = 3.76, p = 0.0006). Furthermore, the HR for AIDS/HIV consistently predicted shortened survival in both early (I–II) and advanced stages (III–IV). Although, the HR for HIV/AIDS was not explained by treatment, a moderate amount (15–30%) of the hazard was explained by their associations with other co-morbidities. In a retrospective case-control study of patients with NSCLC (38 HIV+ and 38 age matched patients of undetermined HIV status) reported in 2003 (not yet published in full), TNM stage, PS, and HIV status were the independent prognostic factors. TNM distribution was identical in the two groups and did not explain the difference in survival. However, the higher proportion of patients with PS ≥2 in the HIV+ group with lung cancer might have contributed to their poorer survival. The reasons why HIV status is associated with poorer outcome are unclear. In particular, CD4+ cell count and AIDS status at lung cancer diagnosis do not seem to influence prognosis, nor is there a correlation between lung cancer stage and CD4 counts. HIV infection was responsible for death in <30% of cases of lung cancer in the most recent series in which patients were less severely immunosuppressed than in earlier studies.

The general consensus therefore seems to be that these patients are apt to be young, male, heavy smokers, have peripheral adenocarcinomas, advanced disease at presentation, a poor PS, tolerate radiation and medical treatment poorly, and have a poor prognosis no matter what the treatment.

TREATMENT

Data on the management of HIV+ patients with lung cancer come mainly from the abovementioned case-control series and case reports describing adverse effects. There are no published prospective clinical trials assessing efficacy and toxicity of chemotherapy regimens, used either alone or combined with radiotherapy.

Surgery

Data on the surgical treatment of HIV+ patients with lung cancer are summarised in table 5. Most patients do not have a low CD4+ cell count and are, in fact, in good health, although PS is rarely reported. Postoperative complications are limited to one death due to infection among 18 patients. Survival data vary. Five of seven patients with stage IA disease included in two series and undergoing surgery died within 5 months. However, these studies were performed before the introduction of HAART and it is not known if the cause of death was due to HIV infection or tumour progression. In contrast, a recent report describing two patients with CD4+ cell counts <200 mm³ had no postoperative complications and acceptable survival at 12 months (stage IIIA) and 20 months (stage IIB). Surgery should therefore be considered for localised or even locally advanced disease in patients with adequate pulmonary function and good general status, regardless of immune status.

Chemotherapy

The results of chemotherapy for HIV+ patients with lung cancer are few and imprecise. Chemotherapy has been used to treat metastatic disease but has also been used in combination with radiotherapy for locally advanced disease and perioperatively. Its use seems less frequent in HIV+ patients with lung cancer than in controls with undetermined HIV status, whatever the disease stage, perhaps because of poorer PS. Treatment regimens are rarely described in detail. Efficacy and toxicity are difficult to analyse in the absence of clinical trials, but a recent study performed in England since the introduction of HAART suggested no difference in survival between HIV+ and HIV− patients (4 months in each group). Progression rates of 50–70% have been reported after first line chemotherapy.

Some authors suggest that poor results could be related to drug interactions and additive toxicity of cytotoxic and antiretroviral drugs. The non-nucleoside reverse transcriptase inhibitors efavirenz, delavirdine, and nevirapine are mainly metabolised by the cytochrome P450 system. However, protease inhibitors (especially ritonavir and indinavir) have a strong affinity for and inhibit cytochrome P450 3A4 which is also the main metabolic pathway used by ifosphamide, docetaxel, paclitaxel, irinotecan, vinca alkaloids, and etoposide. Similarly, cultured tumour cells expressing P-gp have been shown to accumulate paclitaxel and vinblastine in the presence of certain protease inhibitors (saquinavir, ritonavir, and nelfinavir but not indinavir). All non-nucleoside reverse transcriptase inhibitors and most protease inhibitors inhibit P-gp, both improving drug sensitivity in vitro but also potentially increasing toxicity in vivo.

However, the clinical consequences of these pharmacological interactions have not been assessed in humans. Didanosine, stavudine, and zalcitabine have the same peripheral neurological toxicity as regimens using a platinum with a taxane. Similarly, AZT bone marrow toxicity is enhanced when the drug is combined with anticancer chemotherapy. Finally, in HAART treated patients receiving cyclophosphamide, doxorubicin, and etoposide...
based chemotherapy for systemic AIDS related non-Hodgkin’s lymphoma, nadir neutrophil counts were significantly lower and grade 3–4 infections requiring admission to hospital were significantly more frequent (48% v 25%, p = 0.0025) in patients receiving protease inhibitors than in those receiving protease inhibitor sparing HAART regimens.92

The risk of opportunistic infection may also be considered in HIV+ patients with lung cancer receiving chemotherapy. In HAART treated patients receiving chemotherapy for non-Hodgkin’s lymphoma, the CD4+ cell count fell by 50% but recovered within 1 month after chemotherapy. However, the percentage of CD4+ cells was unchanged throughout chemotherapy, as was the plasma HIV viral load.90 CD4+ cell recovery is faster in these patients than in HIV− patients and in HIV+ patients treated by chemotherapy without HAART.90,91 However, the impact of chemotherapy on the immunological status of HIV+ patients with lung cancer has not been evaluated, although opportunistic infections were rare in recent series.4 32 45 62 No specific recommendations have been made on prophylaxis for opportunistic infections in HIV+ patients receiving chemotherapy. Together, these data suggest that the CD4+ cell count should be regularly monitored (every month) during and after a shorter smoking history. However, the carcino-genic risk of lung cancer, especially NSCLC, seems to be greater in the HIV+ population, but differences in smoking habits are certainly of the nucleoside analogue reverse transcriptase inhibitors AZT and lamivudine and their interaction with smoking—needs to be examined. Patients must be informed of this increased risk and strongly encouraged to stop smoking. Screening with low dose spiral CT scanning should be considered in this high risk population. Peripheral adenocarcinoma tends to predominate, perhaps making surgery a more frequent option. Surgery seems as effective as in the general lung cancer population, while prospective studies of the efficacy and toxicity of chemotherapy and radiotherapy are needed to optimise patient management. The important question as to why the risk of lung cancer (especially NSCLC) in HIV+/AIDS patients is increased remains, as yet, not fully answered or completely understood.

CONCLUSIONS

There are no data on the efficacy of thoracic radiotherapy on HIV+ patients with locally advanced or inoperable lung cancer. Toxicity data are summarised in table 6. Grade 3–4 toxicity was observed in four of 13 patients (31%).4 45 62 However, case reports have commented on severe oesophagitis and rapid stricture formation in patients receiving radiation therapy for lung cancer.91 92 Severe adverse effects had previously been reported after thoracic radiotherapy for Kaposi’s sarcoma in HIV+ patients.93 94 Possible causes include reduced mucosal repair capacities,95 96 98 notably due to glutathione antioxidant deficiency,99 100 and concurrent opportunistic oesophageal infections (such as Candida, herpes, cytomegalovirus, Cryptococcus) in those with AIDS.101 102 Available data suggest that HIV+ patients with lung cancer should be treated as recommended for the general population. However, it is advisable to avoid aggressive combinations carrying a high risk of chemotherapy toxicity and/or drug interactions. The use of conformal radiotherapy may limit the risk of adverse effects.103 Finally, close attention must be paid to adverse effects of chemotherapy and radiotherapy in this setting.

REFERENCES

HIV-related lung cancer


LUNG ALERT

Allergen sensitisation and impaired lung function in children

This study investigated the role of allergic sensitisation early in life as a factor which may contribute to the progressive loss of pulmonary function in children with persistent asthma. 1314 children were followed from birth to age 13. IgE measurements and parental interviews about their child’s asthma were conducted regularly. Allergen exposure, lung function, bronchodilator response, and histamine challenge were also assessed.

Sensitisation and concomitant exposure to high levels of house dust mite, cat and dog hair allergens in the first 3 years of life was associated with loss of lung function at school age: FEV1/FVC 87.4 v 92.6 for those not sensitised (p<0.0001), and MEF50 86.4 and 101.5 (p = 0.0031) respectively. In sensitised children with wheeze, high exposure levels also enhanced the development of airway hyperresponsiveness. Sensitisation and exposure later in life had less effect and seasonal allergens had no role. 90% of children with wheeze but no atopy were asymptomatic at school age and retained normal lung function to age 13.

This study shows that continuing allergic airway inflammation beginning in the first 3 years of life contributes to airway hyperresponsiveness and impairment of lung function at school age. Further investigation is required to see if early inhaled corticosteroid treatment in atopic wheezy infants can prevent loss of lung function. In non-atopic wheezing children the need for corticosteroids on a regular basis should be reassessed as they have a good prognosis.

U Gupta
Senior House Officer, William Harvey Hospital, Kent, UK; urmi33@hotmail.com
Lung cancer in HIV infected patients: facts, questions and challenges

J Cadranel, D Garfield, A Lavolé, M Wislez, B Milleron and C Mayaud

Thorax 2006 61: 1000-1008
doi: 10.1136/thx.2005.052373

Updated information and services can be found at:
http://thorax.bmj.com/content/61/11/1000

These include:

References
This article cites 95 articles, 17 of which you can access for free at:
http://thorax.bmj.com/content/61/11/1000#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: infectious diseases (968)
- HIV/AIDS (194)
- Health effects of tobacco use (211)
- Lung cancer (oncology) (670)
- Lung cancer (respiratory medicine) (670)
- Lung neoplasms (608)
- Screening (oncology) (407)
- Health education (1223)
- Smoking (1037)
- Tobacco use (1039)
- Epidemiologic studies (1829)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/